PhiTech Bioinformatics
Private Company
Funding information not available
Overview
PhiTech Bioinformatics is a private, early-stage diagnostics company leveraging artificial intelligence to analyze combined genomic and transcriptomic data. Its core offering is the G&M platform, which aims to significantly improve diagnostic yield for complex genetic conditions, addressing critical unmet needs in the rare disease and hereditary cancer markets. Founded in 2019, the company has raised a seed round, completed a prominent accelerator program, and is targeting diagnostic labs, hospitals, and biopharma partners as its primary customers.
Technology Platform
G&M: A web-based, AI-powered diagnostic platform that integrates whole exome/genome sequencing (WES/WGS) with RNA-Seq data. It uses a proprietary AI algorithm for automated gene prioritization and leverages structured control cohorts to identify functional transcriptomic aberrations, aiming to improve diagnostic yield.
Opportunities
Risk Factors
Competitive Landscape
PhiTech competes in the growing market for AI-powered genomic interpretation software. Competitors range from large, established players like Sophia Genetics and Fabric Genomics to numerous startups specializing in AI for variant prioritization. Its key differentiator is the deep integration of functional transcriptomic (RNA-Seq) data with genomic data, a more comprehensive but also more complex approach than DNA-only analysis.